Sab Biotherapeutics earnings were -$398.4k for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest SABS earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$18.9M, up 11.9% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, SABS reported annual earnings of $13.3M, with -138.9% growth.
Sab Biotherapeutics Earnings Reports & History FAQ
What were Sab Biotherapeutics's earnings last quarter?
Sab Biotherapeutics (NASDAQ: SABS) reported Q1 2026 earnings per share (EPS) of -$0.35, up 37.5% year over year. Total SABS earnings for the quarter were -$18.87 million. In the same quarter last year, Sab Biotherapeutics's earnings per share (EPS) was -$0.56.
Is Sab Biotherapeutics profitable or losing money?
As of the last Sab Biotherapeutics earnings report, Sab Biotherapeutics is currently losing money. Sab Biotherapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2026 was -$398.43 thousand, a 98.84% decrease year over year.
What was SABS's earnings growth in the past year?
As of Sab Biotherapeutics's earnings date in Q2 2026, Sab Biotherapeutics's earnings has grown year over year. SABS earnings in the past year totalled -$398.43 thousand.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.